

## **SUPPLEMENTARY MATERIALS**

**Supplementary Table 1. Baseline variables for all the survivors who had follow-up data\***

Variable	Total population N=243	Hypo-inflammatory N=173	Hyper-inflammatory N=70	P value‡
<b>Baseline patient data</b>				
Age, years	52 (41,60)	52 (40,60)	52 (43,61)	0.55
Female, N (%)	130 (53)	90 (52)	40 (57)	0.48
White, N (%)	204 (84)	147 (85)	57 (81)	0.43
Diabetes, N (%)	55 (23)	31 (18)	24 (34)	0.01
BMI, kg/m <sup>2</sup>	30 (26,37)	29 (25,37)	31 (26,36)	0.71
Living at home independently, N (%)	214 (88)	153 (88)	61 (87)	0.83
<b>Baseline intensive care data</b>				
Medical ICU, N (%)	143 (59)	104 (60)	39 (56)	0.57
APACHE III	85 (68,106)	78 (61,94)	108 (87,125)	<0.01
PaO <sub>2</sub> :FiO <sub>2</sub>	153 (115,202)	152 (113,202)	154 (130,205)	0.54
Shock at baseline, N (%)	98 (40)	53 (31)	45 (64)	<0.01
Primary lung injury risk factor, N (%)				0.13§
Pneumonia	174 (72)	129 (75)	45 (64)	
Non-pulmonary infection	49 (20)	29 (17)	20 (29)	
Aspiration	15 (6)	12 (7)	3 (4)	
Trauma	2 (1)	2 (1)	0 (0)	
<b>Organ-failure-free days to day 14¶</b>				
Cardiovascular	12 (9,13)	12 (10,13)	10 (6,12)	<0.01
Coagulation	14 (14,14)	14 (14,14)	14 (10,14)	<0.01
Liver	14 (14,14)	14 (14,14)	14 (5,14)	<0.01
Renal	14 (14,14)	14 (14,14)	14 (5,14)	<0.01
Ventilator-free days to day 28**	23 (18,25)	24 (20,26)	20 (15,23)	<0.01
ICU LOS, days	10 (7,16)	9 (7,14)	14 (9,19)	<0.01
Hospital LOS, days	16 (11,26)	15 (10,22)	22 (14,34)	<0.01

APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; FiO<sub>2</sub>, fraction of inspired oxygen; ICU, intensive care unit; LOS, length of stay; PaO<sub>2</sub>, partial pressure of arterial oxygen.

\*Median values (IQR) are presented unless otherwise indicated.

‡Wilcoxon rank-sum test was used for continuous variables and Fisher's exact test for proportions, unless stated otherwise.

§Chi-square test.

¶In this cohort of survivors, these variables represent the number of days without organ/system failure (as defined herein) during the first 14 days after randomization. Organs/systems were considered failure-free after patients were discharged from the hospital. Cardiovascular failure was defined as a systolic blood pressure ≤ 90 mmHg or use of vasopressor; coagulation failure defined as platelet count ≤ 80,000 per cubic millimeter; liver failure defined as serum bilirubin level of ≥ 2.0 mg per deciliter (34 μmol per liter); renal failure defined as serum creatinine ≥ 2.0 mg per deciliter (180 μmol per liter).

\*\* In this cohort of survivors, this variable represents the number of days without ventilator assistance during the first 28 days after randomization.

**Supplementary Table 2. Comparison of changes between 6 and 12 months\***

Patient-reported outcome domain-survey instrument†	Hypo-inflammatory N=160	Hyper-inflammatory N=59	P Value‡
<b>Mortality between 6 and 12 months**</b>	5 (3%)	4 (6%)	0.28
<b>Health-related quality of life: SF-36 (normalized scores)</b>			
Physical Functioning	0.0 (-4.2,4.2)	2.1 (0.0,6.3)	0.01
Physical Component Summary	1.6 (-4.8,6.3)	2.2 (-3.0,8.0)	0.26
Mental Health	0.0 (-8.4,5.6)	0.0 (-2.8,5.6)	0.08
Mental Component Summary	-1.2 (-7.2,5.2)	2.5 (-2.1,9.5)	0.01
<b>Health-related quality of life: EQ-5D-3L</b>			
Utility score	0.0 (-0.1,0.1)	0.0 (0.0,0.1)	0.22
Visual analogue scale	5.0 (-10.0,15.0)	1.0 (-6.0,13.0)	0.97
<b>Physical functioning</b>			
Functional Performance Inventory-Short Form	0.0 (-0.2,0.2)	0.2 (0.0,0.5)	0.01
<b>Mental health symptoms</b>			
Anxiety subscale of HADS	0.0 (-2.0,2.0)	-1.0 (-3.8,0.0)	0.01
Depression subscale of HADS	0.0 (-1.0,2.0)	0.0 (-3.5,1.0)	0.03
Post-traumatic stress disorder: IES-R	0.0 (-0.2,0.3)	-0.1 (-0.6,0.1)	0.01
<b>Performance-based physical outcomes</b>	<b>N=37</b>	<b>N=16</b>	
6-Minute walk distance, % predicted	4 (-1,14)	8 (1,16)	0.59
4 m gait speed, m/s	0.0 (0.0,0.1)	0.0 (0.0,0.2)	0.71
Hand grip, % predicted§	7 (-1,18)	5 (-4,10)	0.23
Muscle strength, % maximum	0 (-2,3)	2 (-2,7)	0.39
Maximal inspiratory pressure, % predicted	6 (-1,17)	11 (4,32)	0.16
FEV <sub>1</sub> % predicted	1 (-3,6)	0 (-5,3)	0.52
FVC % predicted	1 (-4,4)	-1 (-3,3)	0.65
<b>Cognitive function (for all tests, higher score is better)¥</b>	<b>N=101</b>	<b>N=40</b>	
Executive function	0.0 (0.0,1.0)	1.0 (0.0,2.2)	0.29
Language	0.5 (-2.2,5.2)	1.0 (-3.5,4.0)	0.94
Verbal reasoning and concept formation	0.5 (-1.0,2.0)	1.0 (0.0,2.0)	0.68
Working memory and attention	0.0 (-1.2,1.0)	0.0 (-1.0,1.5)	0.41
Immediate memory	0.0 (-1.2,2.0)	1.0 (-1.0,2.0)	0.62
Delayed memory	0.0 (-1.0,2.0)	1.0 (-1.0,2.0)	0.55

FEV<sub>1</sub>, forced expiratory volume first second; FPI-Short Form overall score and subscale scores (for each, range: 0–3; higher score is better); FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale-revised; SF-36, Medical Outcomes Study Short Form 36 V.2.

\*Includes patients who completed both 6- and 12-month assessments. Median values (IQR) are presented unless otherwise indicated.

\*\* Five out of 166 and 4 out of 67 patients who completed 6-month assessment died prior to 12-month assessment in the hypo- and hyper-inflammatory subphenotypes, respectively.

‡Wilcoxon rank-sum test was used for continuous variables and Fisher’s exact test for proportions

†Explanation of scoring: SF-36 physical function and mental health normalized scores (mean=50; SD =10; range: 0–100; higher score is better); SF-36 physical and mental health summary normalized scores (mean=50; SD=10; higher score is better); EQ-5D utility score (range: –0.11 to 1.0; higher score is better) and visual analogue scale score (range: 0–100; higher score is better); FPI-Short Form overall score and subscale scores (for each, range: 0–3; higher score is better); HADS subscale scores for anxiety and depression (for each, range: 0–21; lower score is better, with scores ≥8 indicating substantial symptoms); IES-R (range: 0–4; lower score is better, with scores ≥1.6 indicating substantial symptoms); manual muscle testing score (range: 0–60; higher score is better, with scores <48 indicating ‘ICU-acquired weakness’).

§Greater handgrip of right and left hands.

¥Explanation of scoring: executive function was evaluated with the Hayling Sentence Completion Test scaled score (range 1–10); language was evaluated with the Controlled oral word association total score; verbal reasoning and concept formation was evaluated with the Similarities age-adjusted scaled score (range 1–19); attention and working memory was evaluated with the Digit Span age-adjusted scaled score (range 1–19); and immediate and delayed memory was evaluated with the Logical Memory I and II age-adjusted scaled scores (range 1–19).

**Supplementary Table 3. 6-month comparison, by treatment group**

Patient-reported outcome domain-survey instrument	Placebo Group				Rosuvastatin Group			
	Total N=124	Hypo-inflammatory N=85	Hyper-inflammatory N=39	P Value	Total N=108	Hypo-inflammatory N=80	Hyper-inflammatory N=28	P Value
<b>Health-related quality of life: SF-36 (normalized scores)</b>								
Physical Functioning	32 (23-47)	32 (23-49)	32 (22-47)	0.57	37 (23-49)	38 (23-49)	34 (19-40)	0.10
Physical Component Summary	34 (28-46)	36 (27-47)	33 (30-41)	0.45	36 (28-49)	37 (28-49)	35 (27-47)	0.52
Mental Health	47 (35-58)	47 (34-58)	50 (39-58)	0.85	42 (33-53)	44 (30-53)	42 (33-50)	0.67
Mental Component Summary	50 (37-58)	50 (37-58)	50 (38-56)	0.92	44 (32-56)	47 (32-56)	39 (33-47)	0.31
<b>Health-related quality of life: EQ-5D-3L</b>								
Utility score	0.78 (0.47-0.83)	0.78 (0.49-0.83)	0.71 (0.45-0.83)	0.67	0.77 (0.58-0.84)	0.80 (0.60-0.84)	0.73 (0.49-0.84)	0.32
Visual analogue scale	70 (50-80)	65 (50-80)	75 (48-87)	0.77	75 (60-82)	75 (60-85)	72 (52-80)	0.55
<b>Physical functioning</b>								
Functional Performance Inventory-Short Form	2.0 (1.4-2.5)	2.0 (1.4-2.6)	1.9 (1.3-2.5)	0.73	1.9 (1.3-2.5)	2.0 (1.3-2.6)	1.6 (1.1-2.3)	0.06
<b>Mental health symptoms</b>								
Anxiety subscale of HADS	6 (3-10)	5 (2-10)	8 (4-11)	0.14	7 (3-11)	7 (3-11)	8 (5-13)	0.49
Depression subscale of HADS	5 (2-10)	5 (2-9)	5 (2-11)	0.73	6 (2-10)	6 (2-10)	5 (3-10)	1.00
Post-traumatic stress disorder score- IES-R	0.7 (0.2-1.6)	0.6 (0.1-1.5)	1.0 (0.2-1.9)	0.18	1.0 (0.3-1.7)	0.9 (0.3-1.5)	1.3 (0.4-1.9)	0.30
<b>In-patient healthcare utilization</b>								
Physical rehabilitation, N (%) †	29 (23)	16 (19)	13 (33)	0.11	22 (20)	17 (21)	5 (18)	1.00
Skilled nursing, N (%) †	8 (6)	3 (4)	5 (13)	0.11	10 (9)	7 (9)	3 (11)	0.71
Hospital re-admission, N (%)	35 (28)	23 (27)	12 (31)	0.67	33 (31)	26 (32)	7 (25)	0.63
No. admissions to hospital, among those with admission	1.0 (1.0-3.0)	1.0 (1.0-2.5)	1.0 (1.0-3.0)	1.00	1.0 (1.0-2.0)	1.0 (1.0-2.0)	1.0 (1.0-2.5)	0.61

**Supplementary Table 3, cont'd**

Performance-based physical outcomes	Placebo Group				Rosuvastatin Group			
	Total N=37	Hypo- inflammatory N=25	Hyper- inflammatory N=12	P Value‡	Total N=28	Hypo- inflammatory N=19	Hyper- inflammatory N=9	P Value
6-Minute walk distance, % predicted	66 (48-80)	66 (49-80)	68 (43-82)	0.96	66 (49-79)	66 (46-77)	65 (56-79)	0.62
4 m gait speed, m/s	0.9 (0.8-1.2)	0.9 (0.8-1.2)	0.9 (0.7-1.1)	0.45	0.9 (0.8-1.0)	0.9 (0.8-1.0)	0.9 (0.8-0.9)	0.66
Hand Grip, Greater % predicted	82 (68-101)	91 (70-101)	77 (59-90)	0.25	77 (58-111)	76 (48-118)	82 (63-88)	0.81
Muscle strength, % maximum	95 (92-100)	95 (93-100)	92 (88-95)	0.04	96 (92-98)	97 (91-98)	95 (93-100)	0.47
Maximal Inspiratory Pressure, % predicted	83 (60-110)	92 (66-114)	72 (58-99)	0.16	93 (54-110)	93 (56-111)	94 (55-107)	0.77
FEV <sub>1</sub> % predicted	78 (60-90)	85 (63-95)	73 (52-84)	0.24	80 (68-92)	76 (67-88)	88 (74-96)	0.33
FVC % predicted	77 (61-94)	80 (63-97)	70 (58-80)	0.21	78 (64-92)	72 (63-93)	87 (75-91)	0.69
<b>Cognitive function status</b>	<b>N=76</b>	<b>N=50</b>	<b>N=26</b>		<b>N=51</b>	<b>N=39</b>	<b>N=12</b>	
Executive function	5 (3-6)	5 (3-6)	6 (3-6)	0.57	5 (4-6)	5 (4-6)	4 (2-6)	0.16
Language	33 (24-39)	33 (23-39)	35 (24-40)	0.78	30 (23-40)	32 (25-41)	25 (17-31)	0.10
Verbal reasoning and concept formation	11(7-12)	10 (7-11)	11 (9-12)	0.16	10 (7-12)	10 (7-13)	8 (6-10)	0.05
Working memory and attention	10 (8-11)	10 (8-11)	10 (8-11)	0.79	9 (7-12)	9 (8-12)	8 (6.0-12.0)	0.16
Immediate memory	9 (6-11)	9 (6-11)	10 (6-12)	0.51	9 (6-12)	9 (7-12)	6 (5-8)	0.01
Delayed memory	9 (7-11)	8 (7-11)	9 (7-12)	0.39	8 (6-11)	9 (7-11)	6 (5-7)	<0.01

COWA, controlled oral word association; EQ-5D-3L, EuroQol- 5 dimensions- 3 levels; FEV<sub>1</sub>, forced expiratory volume first second; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale-revised; NCSE, neurobehavioral cognitive status examination; SF-36, Medical Outcomes Study Short Form 36 V.2.

\*Median values (IQR) are presented unless otherwise indicated. Higher scores are better, except for mental health outcomes.

‡Wilcoxon rank-sum test was used for continuous variables and Fisher's exact test for proportions.

\*Normed using population mean of 50 and SD of 10.

¶Includes number of patients discharged from hospital to these facilities or admitted to these facilities in the course of follow-up

**Supplementary Table 4. 12-month outcomes, by treatment group\***

Patient-reported outcome domain-survey instrument	Placebo Group				Rosuvastatin Group			
	Total N=115	Hypo-inflammatory N=80	Hyper-inflammatory N=35	P Value	Total N=104	Hypo-inflammatory N=80	Hyper-inflammatory N=24	P Value
<b>Health-related quality of life: SF-36 (normalized scores)</b>								
Physical Functioning	36 (25-51)	34 (23-49)	38 (28-53)	0.30	37 (25-51)	38 (23-51)	36 (28-44)	0.86
Physical Component Summary	37 (27-50)	35 (26-48)	40 (30-51)	0.25	39 (30-51)	40 (30-52)	39 (33-45)	0.59
Mental Health	50 (36-56)	44 (33-56)	53 (44-58)	0.07	42 (30-58)	39 (30-58)	51 (36-56)	0.73
Mental Component Summary	49 (38-58)	47 (36-57)	55 (45-59)	0.05	44 (32-58)	40 (31-58)	51 (34-57)	0.42
<b>Health-related quality of life: EQ-5D-3L</b>								
Utility score	0.77 (0.60-0.84)	0.76 (0.60-0.84)	0.79 (0.60-0.85)	0.30	0.77 (0.51-0.84)	0.77 (0.51-0.85)	0.78 (0.69-0.81)	0.89
Visual analogue scale	75 (60-85)	75 (50-85)	75 (65-85)	0.57	80 (50-90)	80 (50-90)	80 (75-85)	0.82
<b>Physical functioning</b>								
Functional Performance Inventory-Short Form	2.1 (1.3-2.6)	1.9 (1.3-2.5)	2.2 (1.6-2.7)	0.24	2.0 (1.5-2.6)	2.1 (1.6-2.6)	1.9 (1.4-2.3)	0.29
<b>Mental health symptoms</b>								
Anxiety subscale of HADS	6 (2-10)	6 (3-10)	6 (2-9)	0.80	7 (3-10)	7 (3-11)	6 (3-10)	0.69
Depression subscale of HADS	5 (1-10)	6 (3-11)	3 (1-9)	0.15	6 (2-9)	6 (2-10)	5 (1-7)	0.18
Post-traumatic stress disorder score- IES-R	0.6 (0.1-1.6)	0.6 (0.1-1.6)	0.5 (0.2-1.1)	0.83	0.8 (0.3-1.7)	0.7 (0.3-1.7)	0.8 (0.3-1.7)	0.78
<b>In-patient healthcare utilization</b>								
Physical rehabilitation, N (%) †	6 (5)	3 (4)	3 (9)	0.38	2 (2)	2 (2)	0 (0)	1.00
Skilled nursing, N (%) †	4 (3)	3 (4)	1 (3)	1.00	2 (2)	2 (2)	0 (0)	1.00
Hospital re-admission, N (%)	28 (24)	16 (20)	12 (34)	0.16	31 (30)	26 (32)	5 (21)	0.31
No. admissions to hospital, among those with admission	1.0 (1.0-2.2)	2.0 (1.0-3.0)	1.0 (1.0-2.0)	0.07	1.0 (1.0-2.0)	1.0 (1.0-2.0)	2.0 (1.0-3.0)	0.21

Supplementary Table 4, cont'd

Performance-based physical outcomes	Placebo Group				Rosuvastatin Group			
	Total N=29	Hypo- inflammatory N=20	Hyper- inflammatory N=9	P Value‡	Total N=24	Hypo- inflammatory N=17	Hyper- inflammatory N=7	P Value
6-Minute walk distance, % predicted	72 (52-84)	67 (52-80)	74 (60-92)	0.41	74 (63-85)	75 (65-85)	67 (54-78)	0.48
4 m gait speed, m/s	1.0 (0.8-1.2)	1.0 (0.8-1.2)	1.0 (0.8-1.1)	0.57	1.0 (0.9-1.1)	1.0 (0.9-1.1)	1.0 (0.8-1.2)	0.88
Hand Grip, Greater % predicted	91 (72-107)	93 (78-106)	76 (66-111)	0.37	86 (69-111)	91 (65-129)	81 (69-98)	0.35
Muscle strength, % maximum	97 (93-98)	97 (93-100)	97 (95-97)	0.59	97 (93-100)	97 (93-100)	98 (96-100)	0.44
Maximal Inspiratory Pressure, % predicted	105 (77-127)	116 (77-123)	92 (82-136)	0.92	109 (78-115)	110 (86-115)	85 (64-108)	0.38
FEV <sub>1</sub> % predicted	81 (62-98)	88 (67-99)	68 (58-90)	0.40	80 (72-92)	79 (73-90)	89 (64-95)	0.75
FVC % predicted	81 (63-96)	84 (70-98)	63 (60-86)	0.22	80 (70-91)	78 (72-91)	90 (64-91)	1.00
<b>Cognitive function status</b>	<b>N=76</b>	<b>N=53</b>	<b>N=23</b>		<b>N=65</b>	<b>N=48</b>	<b>N=17</b>	
Executive function	6 (4-6)	5 (4-6)	6 (5-6)	0.16	6 (5-6)	6 (5-6)	5 (4-6)	0.17
Language	30 (22-38)	31 (25-38)	27 (20-37)	0.49	33 (23-41)	36 (24-43)	24 (22-35)	0.17
Verbal reasoning and concept formation	11 (8-12)	10 (8-13)	11 (9-12)	0.41	9 (8-12)	10 (9-13)	9 (7-10)	0.03
Working memory and attention	9 (7-11)	9 (8-11)	10 (7-11)	0.99	9 (8-11)	9 (8-11)	9 (7-9)	0.19
Immediate memory	9 (7-11)	8 (7-11)	9 (7-11)	0.47	9 (7-11)	9 (7-12)	7 (5-10)	0.04
Delayed memory	9 (7-11)	9 (7-11)	8 (7-11)	0.75	9 (7-11)	9 (7-11)	8 (6-10)	0.18

COWA, controlled oral word association; EQ-5D-3L, EuroQol- 5 dimensions- 3 levels; FEV<sub>1</sub>, forced expiratory volume first second; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale-revised; NCSE, neurobehavioral cognitive status examination; SF-36, Medical Outcomes Study Short Form 36 V.2.

\*Median values (IQR) are presented unless otherwise indicated. Higher scores are better, except for mental health outcomes.

‡Wilcoxon rank-sum test was used for continuous variables and Fisher's exact test for proportions.

\*Normed using population mean of 50 and SD of 10.

¶Includes number of patients discharged from hospital to these facilities or admitted to these facilities in the course of follow-up

**Supplementary Table 5. 6- and 12-month outcomes of patient subgroup with baseline data**

<b>Baseline Data*</b>	<b>Total population N=98</b>	<b>Hypo-inflammatory N=65</b>	<b>Hyper-inflammatory N=33</b>	<b>P‡</b>
<b>Health-related quality of life: SF-36 (normalized scores)†</b>				
Physical Functioning	50 (32,57)	49 (31,57)	53 (35,57)	0.46
Physical Component Summary	48 (35,56)	44 (35,56)	53 (37,58)	0.46
Mental Health	50 (36,58)	50 (36,58)	51 (37,58)	0.84
Mental Component Summary	52 (37,58)	50 (39,57)	53 (35,58)	0.91
<b>Health-related quality of life: EQ-5D-3L</b>				
Utility score	0.83 (0.76,1.00)	0.81 (0.71,1.00)	0.83 (0.77,1.00)	0.80
Visual analogue scale	80 (60,90)	78 (58,90)	85 (70,90)	0.42
<b>Physical functioning</b>				
Functional Performance Inventory-Short Form	2.4 (1.9,2.7)	2.3 (1.8,2.7)	2.4 (2.0,2.7)	0.55
<b>Six-month Data</b>				
	<b>N=91</b>	<b>N=59</b>	<b>N=32</b>	<b>P</b>
<b>Health-related quality of life: SF-36 (normalized scores)</b>				
Physical Functioning	38 (25,49)	40 (25,51)	36 (25,47)	0.24
Physical Component Summary	37 (31,48)	38 (29,49)	35 (31,45)	0.52
Mental Health	50 (36,58)	51 (33,58)	50 (38,58)	0.77
Mental Component Summary	52 (36,58)	53 (34,58)	49 (39,57)	0.83
<b>Health-related quality of life - EQ-5D-3L</b>				
Utility score	0.79 (0.58,0.84)	0.80 (0.52,0.84)	0.78 (0.67,0.83)	0.95
Visual analogue scale	75 (60,84)	70 (60,80)	75 (50,85)	0.83
<b>Functional performance</b>				
FPI	2.0 (1.5,2.5)	2.0 (1.6,2.6)	1.9 (1.3,2.5)	0.29
<b>Twelve-month Data</b>				
	<b>N=83</b>	<b>N=56</b>	<b>N=27</b>	<b>P</b>
<b>Health-related quality of life: SF-36 (normalized scores)</b>				
Physical Functioning	39 (28,53)	40 (28,54)	38 (27,52)	0.71
Physical Component Summary	40 (30,53)	40 (30,55)	39 (29,47)	0.30
Mental Health	50 (33,56)	46 (31,58)	53 (47,56)	0.20
Mental Component Summary	50 (36,58)	47 (31,58)	55 (46,57)	0.16
<b>Health-related quality of life - EQ-5D-3L</b>				
Utility score	0.79 (0.59,0.86)	0.79 (0.53,1.00)	0.78 (0.71,0.84)	0.94
Visual analogue scale	75 (60,85)	75 (50,88)	75 (70,85)	0.79
<b>Functional performance</b>				
FPI	2.2 (1.6,2.6)	2.2 (1.6,2.6)	2.2 (1.5,2.7)	0.85

EQ-5D-3L, EuroQol- 5 dimensions- 3 levels; SF-36, Medical Outcomes Study Short Form 36 V.2.

\*Data represent the patients' scores prior to hospitalization based on retrospective assessment.

‡Wilcoxon rank-sum test was used for continuous variables and Fisher's exact test for proportions.

†Explanation of scoring: SF-36 physical function and mental health normalized scores (mean=50; SD =10; range: 0–100; higher score is better); SF-36 physical and mental health summary normalized scores (mean=50; SD=10; higher score is better); EQ-5D utility score (range: –0.11 to 1.0; higher score is better) and visual analogue scale score (range: 0–100; higher score is better); FPI-Short Form overall score and subscale scores (for each, range: 0–3; higher score is better).



**Supplementary Table 6. Comparison of changes over 6 and 12 months compared to baseline for subset of patients with baseline data**

Variable	Change from baseline to 6 months			Change from baseline to 12 months			Change from 6 to 12 months		
	Hypo-inflammatory (N=59)	Hyper-inflammatory (N=32)	P value	Hypo-inflammatory (N=56)	Hyper-inflammatory (N=27)	P value	Hypo-inflammatory (N=55)	Hyper-inflammatory (N=27)	P value‡
<b>Health-related quality of life - SF-36 (normalized scores)*</b>									
Physical Functioning	-2 (-11 ,0)	-8 (-15,-3)	0.05	-3 (-8,2)	-4 (-13,0)	0.31	0 (-2,6)	4 (0,6)	0.08
Physical Component Summary	-4 (-14,1)	-7 (-17,-0)	0.20	-3 (-9,2)	-8 (-18,-0.7)	0.08	2 (-3,7)	2 (-4,7)	0.85
Mental Health Component Summary	0.0 (-6,6)	0.0 (-4,6)	0.55	-3 (-11,3)	3 (-3,11)	<0.01	0 (-8,3)	0 (-1,6)	0.10
	-0.8 (-8,4.9)	-0.5 (-7,5)	0.69	-1 (-11,3)	3 (-1,15)	0.01	-0.9 (-7,4)	3 (-2,11)	0.05
<b>Health-related quality of life - EQ-5D-3L</b>									
Visual analogue scale	-5 (-15,5)	-5 (-19,6)	0.78	0.0 (-20,10)	-5.0 (-15,10)	1.00	2.5 (-6,11)	2.0 (-8,11)	0.89
Utility score	-0.1 (-0.2,0.0)	0.0 (-0.2,0.0)	0.30	0.0 (-0.2,0.0)	0.0 (-0.2,0.1)	0.43	0.0 (-0.1,0.2)	0.0 (0.0,0.1)	0.98
<b>Functional Performance</b>									
functional Performance Inventory-Short Form	-0.1 (-0.3,0.1)	-0.3 (-0.7,0.0)	0.04	-0.1 (-0.4,0.1)	0.0 (-0.5,0.2)	0.82	0.0 (-0.2,0.3)	0.1 (0.0,0.4)	0.05

EQ-5D-3L, EuroQol- 5 dimensions- 3 levels; FPI; SF-36, Medical Outcomes Study Short Form 36 V.2.

‡Wilcoxon rank-sum test was used for comparisons

\*Explanation of scoring: SF-36 physical function and mental health normalized scores (mean=50; SD =10; range: 0–100; higher score is better); SF-36 physical and mental health summary normalized scores (mean=50; SD=10; higher score is better); EQ-5D utility score (range: –0.11 to 1.0; higher score is better) and visual analogue scale score (range: 0–100; higher score is better); FPI-Short Form overall score and subscale scores (for each, range: 0–3; higher score is better).